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Abstract
Overexpression of the transcription factor Spi-1/PU.1 by transgenesis in mice induces a maturation arrest at the
proerythroblastic stage of differentiation. We have previously isolated a panel of spi-1 transgenic erythroleukemic cell lines
that proliferated in the presence of either erythropoietin (Epo) or stem cell factor (SCF). Using these cell lines, we observed
that EpoR stimulation by Epo down-regulated expression of the SCF receptor Kit and induced expression of the Src kinase
Lyn. Furthermore, enforced expression of Lyn in the cell lines increased cell proliferation in response to Epo, but reduced cell
growth in response to SCF in accordance with Lyn ability to down-regulate Kit expression. Together, the data suggest that
Epo-R/Lyn signaling pathway is essential for extinction of SCF signaling leading the proerythroblast to strict Epo
dependency. These results highlight a new role for Lyn as an effector of EpoR in controlling Kit expression. They suggest
that Lyn may play a central role in during erythroid differentiation at the switch between proliferation and maturation.
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Introduction
Erythropoiesis is critically regulated by a number of growth
factors acting through specific receptors, among which erythro-
poietin (Epo) and stem cell factor (SCF) are essential factors [1].
SCF, the ligand for the Kit receptor, is mainly involved in the
survival and proliferation of immature erythroid progenitors,
whereas Epo is the predominant regulator preventing apoptosis at
the CFU-E/proerythroblast stage of differentiation. The impor-
tance of the SCF/Kit pathway during erythropoiesis was
highlighted in mice with inactivating mutation in the SCF (Sl/Sl
mice) or Kit gene (W/W mice) [2,3]. Mutant mice die in utero
between day 14–16 of gestation with anemia and a profoundly
reduced number of erythroid progenitors in fetal liver demon-
strating the proliferative function mediated by Kit during early
stages of erythropoiesis. Likewise, mice with null mutations in the
genes encoding either Epo or EpoR die at midgestation with a
severe anemia. Fetal livers from these mice contain BFU-E and
CFU-E progenitors, although in reduced number, indicating that
the Epo/EpoR pathway is crucial in regulating survival,
proliferation and terminal differentiation of CFU-E [4]. Thus,
Epo and SCF are growth factors working synergistically to support
erythropoiesis, with SCF exerting a predominant role to expand
early progenitors, while Epo is acting later on to sustain
maturation.
Signaling induced by Epo/EpoR and SCF/Kit is determined
by the temporal and spatial expression of their cognate receptors
at the surface of responsive cells. Kit is expressed from the earliest
committed erythroid progenitor up to the basophilic erythroblastic
stage of differentiation [5,6]. EpoR expression arises at the BFU-E
stage, reaches a maximum at the CFU-E and proerythroblast
stages and declines thereafter [7,8].
In an attempt to dissect the signaling determinants controlling
the expression of EpoR and Kit, we used proerythroblastic cell
lines isolated during the preleukemic step of erythroleukemia
developing in spi-1 transgenic mice [9]. The spi-1 gene encodes the
ETS transcription factor Spi-1/PU.1, a main player regulating the
commitment of multipotent hematopoietic progenitors and the
development of the B lymphoid and monocytic lineages [10–13].
Germline overexpression of the spi-1 transgene induces a
differentiation arrest in the erythroid lineage at the CFU-E/
proerythroblast transition leading to severe anemia [9,14]. In
response to anemia, Epo production is up-regulated [15] causing a
massive expansion of proerythroblasts in the hematopoietic tissues
of diseased mice. It is likely that SCF expressed by stromal cells in
spleen and marrow microenvironments also contributes to the
expansion of these proerythroblasts. Indeed, spi-1 transgenic
proerythroblasts express both Epo and SCF receptors and can
be expanded in vitro in the presence of Epo or SCF.
Using cell lines established from the spleen of various diseased
mice, we observed that each of these cell lines exhibited a
particular growth rate in response to either Epo alone or SCF
alone, and expressed EpoR and Kit in a ratio modulated by the
cytokine used to sustain their proliferation. Starting from this
observation, we investigated the molecular mechanisms control-
ling the expression of Kit and EpoR. We show that Epo down-
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When ectopically expressed in spi-transgenic proerythroblasts, Lyn
favored cell proliferation in response to Epo, but not to SCF.
These biological effects are consistent with the ability of Lyn to
induce a down-regulation of Kit expression. Our findings reveal a
novel aspect of signaling crosstalk between Kit and EpoR and
highlight a central role for Lyn in SCF signaling extinction at the
CFU-E/proerythroblast stage.
Materials and Methods
Cell lines and proliferation assays
The spi-1-transgenic proerythroblastic cell lines (633, 663, 812)
have been previously described in details [9]. Cells were grown in
alpha MEM medium supplemented with 10% fetal bovine serum
(FBS) and SCF or Epo or both cytokines in combination at the
indicated concentrations. Cells were plated at 2610
5 cells/mL and
the number of living cells was monitored at 48 hours by Trypan
blue exclusion using a Vi-Cell analyzer (Beckman Coulter,
Villepinte, France). For cytokine switching experiments, exponen-
tially growing cells were washed 3 times in MEM and then plated
at 2610
5 cells/mL in culture medium with the cytokines indicated.
AG490 (Calbiochem, Strasbourg, France) and JAK inhibitor1
(Calbiochem, Strasbourg, France) were used at a concentration of
10 mM and 20 nM, respectively.
Flow cytometry and antibodies
Untreated cells were incubated for 30 min at 4uC with
Phycoerythrin (PE)-conjugated anti-CD117 (c-Kit) or PE-conju-
gated IgG2b control monoclonal antibodies (BD Pharmingen,
Strasbourg, France). After washing, cells were analyzed on a
FACsortH with the Cellquest software package (Becton Dickinson,
Meylan, France).
DNA constructs and transfection
The wild-type (WT) Lyn cDNA was amplified by RT-PCR from
mRNAs prepared from 663 cells. The Myc epitope (MT) was
added at the cDNA C-terminus by PCR and the MT-Lyn
WT
construct was cloned into the pEF-BOS expression vector by
standard cloning procedures. The mutant Lyn
Y397F cDNA was
generated by mutagenesis of the MT-Lyn
WT construct using the
quickchange site-directed mutagenesis system (Stratagene, La
Jolla, CA) according to the manufacturer’s recommendations.
Cells were nucleofected with 5 mg of plasmid using an Amaxa
nucleofector (Amaxa Biosystems, Ko ¨ln, Germany). Stable trans-
fectants were selected in growth medium containing 800 mg/mL
G418 (Invitrogen, Cergy, France) and Epo (1 U/mL).
Western blotting and antibodies
Whole cell extracts were fractionated by SDS-PAGE, blotted
and visualized as previously described [16]. The following primary
antibodies were used: rabbit anti-Kit antibodies provided by P.
Dubreuil (Inserm, Marseille, France) [17] or from Cell Signaling
(Beverly, MA), anti-EpoR, anti-Lyn and anti-Stat5 antibodies from
Santa Cruz Biotechnology (Santa Cruz, California), anti-phos-
photyrosine 4G10 clone from Upstate Biotechnology (Lake Placid,
NY), anti-phospho-c-Kit (Tyr719) and anti-phospho-Stat5
(Tyr694) from Cell Signaling (Beverly, MA), anti-b actin antibody
from Sigma-Aldrich (St Louis, MO) and anti-myc (epitope 9E10)
from Roche Diagnostics (Mississauga, Ontario, Canada).
Semiquantitative RT-PCR
RNAs were prepared as previously descibed [9]. RNAs were
reverse transcribed using Superscript II reverse transcriptase
(Invitrogen). cDNAs were amplified by RT-PCR with specific
primers for Kit, EpoR and Lyn: Kit-fw59-TCCTCgCCTCCAA-
gAATTg-39 and Kit-rev 59-ggAAgCCTTCCTTgATCATC-39,
EpoR-fw 59- ggCTCCgAAgAAcTTCTgTg-39 and EpoR-rev 59-
CCAggAgCACTACTTCATTg-39, Lyn-fw 59-GATCCAGAG-
GAACAAGGTGA-39 and Lyn-rev 59-TGACATCACCATGCA-
TAGGG-39.
Results
Kit expression is modulated by cytokines
The three proerythroblastic cell lines (633, 663, 812) used in this
study were derived from erythroleukemic spleens of three
individual spi-1 transgenic mice [9]. The cells were continously
amplified in vitro in the presence of either Epo (1 U/mL) or SCF
(100 ng/mL) [18]. Each cell line exhibited characteristic prolifer-
ation rates that were reproducibly observed over times. In
response to either Epo or SCF, 633 cells were highly proliferative,
663 cells showed an intermediary proliferation rate and 812 cells
proliferated at a low rate (Figure 1A). To gain insights into the
possible causes leading to proliferation rate disparity, we analyzed
the expression level of receptors for Epo (EpoR) and SCF (Kit) by
immunoblotting. Different levels of EpoR expression were
detected in each cell line, but these levels were comparable
whether the cells were cultured with Epo or SCF (Figure 1B).
Unexpectedly, the highest EpoR levels were seen in 812 cells that
proliferated poorly in response to Epo. To check for EpoR activity,
we analyzed Stat5 phosphorylation [19,20]. Phosphorylated Stat5
(P-Stat5) was detected in the 3 cell lines grown with Epo with the
highest level seen in 812 cells that exhibited the highest EpoR
expression level. P-Stat5 was undetectable in cells grown with SCF
(Figure 1B). Next, we analyzed Kit expression levels in the 3 cell
lines grown under the 2 cytokines conditions. Clearly, Kit levels
were high in cells exhibiting a robust proliferative response to SCF
(cell lines 633 and 663). As a read out for Kit activity, detection of
the phosphorylated-Y719-Kit form was performed by immuno-
blotting. P-Y719-Kit was clearly seen in all cells grown with SCF,
but not in Epo-cultured cells (Figure 1B). Strikingly, total Kit
expression levels were significantly higher in cells grown with SCF
compared to cells grown with Epo. Modulation in Kit expression
was also detected at the surface of cells grown with Epo or SCF by
flow cytometry analysis. The mean Kit-specific fluorescence (MFI)
level was increased about 2.5 fold in 663 and 812 cells cultured
with SCF compared to cells grown with Epo (Figure 1C). Similar
results were obtained for 633 cells (data not shown). Collectively,
these data suggested that cytokines could modulate Kit expression
levels in leukemic proerythroblastic cells, while no major effect
were seen on Epo-R expression.
Kit expression is under Epo control
Next, we compared the EpoR and Kit expression levels in the
cell lines cultured in a combination of Epo+SCF (SCF was added
in Epo-cultured cells for 5 days) to cells cultured with either Epo
alone or SCF alone. On Western blotting, Kit expression levels
were high with SCF alone, but significantly reduced when Epo was
present (Figure 2A). Similarly, cell surface modulation of Kit
expression was also detected by flow cytometry analysis with a Kit-
specific MFI higher in cells grown with SCF alone than in cells
expanded with Epo+SCF (Figure 2B). These data were evocative
of a modulation of Kit expression by Epo. To check this
hypothesis, we investigated the effects of AG490 and JAK
inhibitor 1, both inhibiting Jak2 kinase activity. P-Stat5 was used
as a read out for the inhibitory effects of AG490 and JAK inhibitor
1. Both inhibitors had similar effects and only data with AG490
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was undetectable on Western blotting in cells cultured with Epo
(1 U/mL), although total Stat5 levels were unchanged (Figure 2C).
Strikingly, inhibition of EpoR signaling in AG490-treated cells was
accompanied by an increase in Kit expression as compared to
untreated cells. The Kit increase was also detected at the cell
surface of AG490-treated cells by flow cytometry analysis
(Figure 2B). Altogether, these data indicated that the modulation
of Kit expression was dependent on Jak2 activity and suggested
that activation of EpoR could act as a repressor of Kit expression.
We next assessed whether the modulation of Kit expression by
Epo affected the proliferation of cells cultured in the presence of a
combination of Epo+SCF (Figure 2D). When Epo (1 U/mL) was
combined with SCF (100 ng/mL) cell growth was similar to that in
the presence of Epo (1 U/mL) alone (Figure 1A), indicating that
Epo and SCF did not cooperate for cell proliferation. In contrast, a
cooperative effect on proliferation was observed when SCF
(100 ng/mL) was combined to Epo at a limiting dilution
(0.1 U/mL) (Figure 2D) since cell growth was comparable to
Epo alone (1 U/mL) (Figure 1A). These data indicated that the
low expression of Kit was the reason why Epo at high dose did not
cooperate with SCF.
To learn more about the molecular mechanisms involved in the
Epo-dependent regulation of Kit protein expression, we first
investigated whether this process was associated to variations in Kit
transcription. The expression level of kit transcripts was analyzed
by semi-quantitative RT-PCR using RNAs extracted from cells
cultured in the presence of either Epo or SCF (Figure 2E). The
expression level of EpoR transcripts was similarly investigated.
Amplification of Kit transcripts was elevated in SCF-cultured cells
but was poorly efficient in Epo-cultured cells whereas EpoR
transcript levels were not affected by cytokines. These data
strongly suggested that the regulation of Kit expression by Epo was
dependent on a transcriptional process.
Figure 1. Proliferation of spi-1 transgenic proerythroblasts and expression of EpoR, Kit and Stat5. A: Cells were continuously cultured in
the presence of Epo (1 U/mL) or SCF (100 ng/mL). Number of living cells was monitored at 24, 48 and 72 hours using the Trypan blue exclusion
staining and a Vi-Cell analyzer (Becton Coulter). Mean number of living cells and standard deviations were determined from 3 independent
experiments performed in duplicate. B: Representative Western blot of lysates from cells grown with Epo (1 U/mL) or SCF (100 ng/mL). Antibodies
raised against the proteins are indicated on the left of the panel. P-Stat5 and P-Kit antibodies detect Stat5 and Kit phosphorylated forms. The blot was
probed with an anti-b-actin antibody to visualize the protein loading. The membrane was exposed in an Imager, and the resulting signal was
quantified using the ImageGauge software package (Fuji, Paris, France). Values were normalized to b actin expression. The fold change in Kit
expression between Epo or SCF-cultured cells is indicated at the bottom of each cell line. C: Representative diagram of flow cytometry analysis
showing cell surface expression of Kit in 663 and 812 cells cultured with Epo (dotted line) or SCF (black line). Control IgG profile is shown in grey. The
table indicates the mean fluorescence intensity (MFI)6SD of positive cells from four independent experiments.
doi:10.1371/journal.pone.0005721.g001
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The above data were obtained with cells continously cultured
with Epo or SCF. Thus, we cannot exclude that they reflected the
abilities of Epo and SCF to favor some cell selection rather than a
genuine process of response to cytokines. Thus, we investigated
whether Kit levels could be reversibly modulated in response to a
change in cytokines. 663 and 812 cells cultured in the continuous
presence of Epo (1 U/mL) were extensively washed and then
switched to SCF (100 ng/mL). 48 hrs later, cell extracts were
analyzed by immunobloting with an anti-Kit antibody. Switching
from Epo to SCF induced a marked increase in Kit level
(Figure 3A). Reciprocally, Kit levels were decreased when cells
were switched from SCF to Epo for 48 hrs (Figure 3B). These
variations in Kit expression were also detected at the cell surface
by flow cytometry analysis. The Kit-specific MFI was increased
when cells were switched from Epo to SCF and conversely was
decreased after switching from SCF to Epo (Figures 3A, 3B).
When cells continuously grown with SCF were switched to various
concentrations of Epo for 48 hrs, Kit expression levels were
reduced in an Epo-dose dependent manner (Figure 3C). The rapid
Figure 2. Down-regulation of Kit expression by Epo. A: Kit and EpoR expression were studied in the 633, 663 and 812 cells grown continuously
in the presence of either Epo (1 U/mL) or SCF (100 ng/mL) or a combination of Epo (1 U/mL)+SCF (100 ng/mL). Whole cell lysates were subjected to
Western blot analysis with antibodies directed against Kit, EpoR and b-actin as a loading control. Western blots are from a representative experiment.
The membrane was exposed in an Imager, and the resulting signal was quantified using the ImageGauge software package (Fuji, Paris, France).
Values were normalized to b actin expression. The fold change in Kit expression between SCF-cultured cells and either Epo or Epo+SCF-cultured cells
is indicated under Kit immunoblotting. B: Representative diagram of flow cytometry analysis showing Kit membrane expression in cells cultured with
SCF (100 ng/mL; black line) or Epo+SCF (dotted line). Control IgG profile is shown in grey. The table indicates the mean fluorescence intensity
(MFI)6SD of four independent experiments. C: AG490 inhibits the down-regulation of Kit by Epo. Cells were cultured for 48 hrs in a medium
containing 10% FBS, 1 U/mL Epo and in the presence or absence (-) of AG490 (10 mM). Representative Western blot analysis of whole cell lysates with
antibodies directed against Kit, Stat5 and phosphorylated Stat5. b-actin was used as loading control. The fold change in Kit expression between
AG490-treated and untreated cells is indicated under Kit immunoblotting. Representative diagram of flow cytometry analysis showing Kit membrane
expression in 663 and 812 cells cultured with Epo and treated (black line) or not (dotted line) with AG490 (10 mM) for 48 hrs. Control IgG profile is
shown in grey. The table indicates the mean fluorescence intensity (MFI)6SD of positive cells in three independent experiments. D: Cells were
cultured for 24, 48 and 72 hrs in the presence of a combination of Epo (1 U/mL)+SCF (100 ng/mL) or Epo (0.1 U/mL)+SCF (100 ng/mL) and viable
cells were numbered. Data are mean6SD of five experiments, each performed in duplicate. E: The regulation of Kit expression is transcriptional: RT-
PCR analysis of Kit and EpoR transcripts in 633, 663 and 812 cells cultured in the presence of either Epo (1 U/mL) or SCF (100 ng/mL). cDNAs were
amplified with specific primers for Kit, EpoR or gapdh as control.
doi:10.1371/journal.pone.0005721.g002
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changes, the absence of cell death (data not shown) during
cytokine changes and the reversibility of the phenomenon
indicated that they did not result from a selection process. We
thus concluded that activation of Epo-R could mediate a fine
regulation on Kit expression.
Lyn is a downstream Epo-R effector expressed in
response to Epo
The next issue was to identify the effectors downstream of EpoR
that may participate in the regulation of Kit expression. According
to the known function of Src kinases in signaling from growth
factors receptors [21], we investigated the expression of Src kinases
in 633, 663 and 812 cells when cultured either in the presence of
Epo or SCF. The expression of Lyn, Lck and Src could be
detected in these cells. We found that Lyn expression was different
according to the cytokines added in the culture medium.
Immunoblotting with the anti-Lyn antibody in Figure 4A showed
that Lyn was expressed in cells cultured with Epo but not with
SCF. In contrast, no differences in Lck and Src expressions were
observed that cells were cultured with either Epo or SCF (data not
shown). Of note, Lyn expression profiles differed in each cell lines
and correlated with EpoR expression levels. Thus, we investigated
whether Epo could regulate Lyn expression. SCF-cultured cells
were extensively washed in culture medium with no cytokine and
then cultured for 48 hrs in the presence of increasing Epo
concentrations. Immunoblotting of cell extracts with the anti-lyn
Figure 3. Reversible down-regulation of Kit in response to Epo. Switch from Epo to SCF (A) and switch from SCF to Epo (B): 663 and 812 cells
continuously cultured with Epo (1 U/mL) or SCF (100 ng/mL) were extensively washed with medium without cytokine and then expanded for 48 hrs
with SCF (100 ng/mL) or Epo (1 U/mL), respectively. Whole cell lysates were subjected to Western blot analysis with antibodies directed against Kit,
EpoR and b-actin as a loading control. The fold change in Kit expression following the switch in cytokines is indicated under Kit immunoblotting.
Representative diagrams of flow cytometry analysis showing Kit expression on the surface of cells expanded with Epo (dotted line) or SCF (black line).
Control IgG profile is shown in grey. The tables indicate the mean fluorescence intensity (MFI)6SD of positive cells in at least four independent
experiments. C: Switch from SCF to various concentrations of Epo. 663 cells cultured with SCF (100 ng/mL) were extensively washed with medium
without cytokine and then expanded for 48 hrs with Epo at doses indicated. Whole cell lysates were subjected to Western blot analysis with
antibodies directed against Kit, EpoR and b-actin as a loading control. The fold decrease in Kit expression following the switch from SCF to various
doses of Epo is indicated under Kit immunoblotting. Western blots are from a representative experiment repeated 3 times.
doi:10.1371/journal.pone.0005721.g003
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dependent manner with levels readily detectable at 0.25 U/mL of
Epo (Figure 4B). Likewise, P-Stat5 activation levels increased with
Epo concentration. Thus, Epo induced both Lyn expression and
Stat5 activation in a dose-dependent manner. To conclusively
confirm the role of EpoR activation in the modulation of Lyn
expression, the effect of AG490 on Lyn expression level was
investigated by Western blotting (Figure 4C). Lyn expression was
abolished when AG490 (10 mM) was added in the culture medium
containing Epo, which indicated that Lyn expression was
dependent on EpoR/Jak2 activation. Together, these data
demonstrated that Lyn expression is under Epo control in spi-1
transgenic proerythroblasts.
To determine whether the variations in Lyn protein expression
were associated to variations in the expression level of Lyn
transcripts, RT-PCR analyses of RNAs prepared from cells
continuously cultured with either Epo or SCF were performed.
Lyn transcripts were only detected in Epo-cultured cells (Figure 4E)
suggesting that Epo might transcriptionally control Lyn expression.
Lyn down-regulates Kit expression
To explore whether Lyn was a link between EpoR activation
and Kit down-regulation, we used an enforced expression strategy.
An expression vector encoding Lyn tagged with a Myc epitope
(MT) at the C-terminus (MT-Lyn
WT) and the neomycine
resistance gene (NeoR) was stably transfected in Epo-cultured
663 cells. Control cells were transfected with an empty vector
encoding NeoR. G418-selected clones were selected in the
presence of Epo and then amplified in the presence of Epo or
SCF. Among those, two MT-Lyn
WT and two control clones were
studied in details and gave similar results. Only data with one
clone are shown herein. Expression of exogenous MT-Lyn
WT was
detected by Western blotting with an anti-MT antibody and Lyn
global expression was measured with an anti-Lyn antibody
Figure 4. Epo controls Lyn expression. A: Lyn and EpoR expression were studied in 633, 663 and 812 cells continuously grown in the presence of
either Epo (1 U/mL) or SCF (100 ng/mL). Whole cell lysates were subjected to Western blot analysis with antibodies directed against Lyn, EpoR and b-
actin as a loading control. B: Switch from SCF to Epo induces the expression of Lyn. 663 and 812 cells cultured with SCF (100 ng/mL) were extensively
washed with medium without cytokine and then expanded for 48 hrs with Epo at the indicated doses. Whole cell lysates were subjected to Western
blot analysis with antibodies directed against Lyn, Stat5, phosphorylated-Stat5 and b-actin as loading control. C: AG490 inhibits the expression of
Lyn. 663 and 812 cells were cultured for 48 hrs in a medium containing 10% serum in the presence or absence of AG490 (10 mM) and in the presence
of Epo (1 U/ml). Whole cell lysates were subjected to Western blot analysis with antibodies to Lyn, EpoR and b-actin. Western blots are from a
representative experiment. D: RT-PCR analysis of Lyn transcription in 633, 663 and 812 cells cultured in the presence of either Epo (1 U/mL) or SCF
(100 ng/mL). DNAs were amplified with specific primers for Lyn or gapdh as control.
doi:10.1371/journal.pone.0005721.g004
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(1 U/mL) or SCF (100 ng/mL), Kit expression levels were
markedly decreased in cells overexpressing Lyn
WT (compare
663-Lyn
WT to 663-neo cells, Figure 5A). In contrast, EpoR
expression was not affected. Next, we generated a vector encoding
a dominant-negative form of Lyn (mutant Y397F) [22] tagged in
its C-terminus (MT-Lyn
Y397F) to inhibit Lyn function. Stable
G418-resistant transfectants were selected and amplified in the
presence of Epo. As illustrated in Figure 5B, expression of MT-
Lyn
Y397F detected by immunoblotting with the MT antibody was
associated with an increase in Kit level in the Epo-cultured cells.
Thus, Lyn inactivation by a dominant-negative mutant allowed an
up-regulation of Kit expression.
The biological consequences of Lyn overexpression were
examined by studying cell proliferation over a 48 hrs period.
Transfected cells continuously maintained in Epo before and
during the selection process remained strictly Epo dependent since
no growth occurred in the absence of Epo. At the three Epo
concentrations tested, the number of living 663-Lyn
WT cells was
approximately 2-fold increased compared to control 663-neo cells
indicating that overexpression of Lyn was associated with a growth
advantage (Figure 5C). In contrast to cells overexpressing Lyn
WT
Figure 5. Expression of Lyn
WT and Lyn
Y397F in 663 cells. (A) A clone of 663 cells stably transfected with pEF-neo Lyn
WT or pEF-Neo empty
vector was expanded in the presence of Epo (1 U/mL) or SCF (100 ng/mL). Whole cell extracts were subjected to Western blot using anti-MT, anti-Lyn,
anti-EpoR, anti-Kit antibodies and anti-b actin as a loading control. The fold increase in Lyn expression and the fold decrease in Kit expression
between pEF-Neo and pEF-neo Lyn
WT transfected cells are indicated under Lyn or Kit immunoblotting. (B) 663 cells were transfected with pEF-neo
Lyn
Y397F or pEF-Neo empty vector. Proliferation of 663 cells expressing Lyn
Y397F and cultured in the presence of Epo (1 U/mL). Whole cell extracts
were subjected to Western blot using an anti-MT, anti-Lyn, an EpoR, an anti-Kit and an anti-b actin antibody as a loading control. The fold increases in
Lyn and Kit expressions between pEF-Neo and pEF-neo Lyn
Y397F transfected cells are indicated under Lyn or Kit immunoblotting. C: Transfected 663-
neo and 663-Lyn
WT cells were plated at 2610
5 cells/mL in medium containing Epo or SCF at concentrations indicated or with no cytokine. Viable cells
were scored after 48 hours. Data are mean6SD of five independent experiments performed in triplicate. *indicates statistical significance by student t
test: P,.05 compared with the control neo-cells. D: Transfected 663-neo and 663-Lyn
Y397F cells were plated at 2610
5 cells/mL in the presence of
increasing concentrations of Epo and viable cells were scored after 48 hours. Data are mean6SD of five independent experiments performed in
triplicate. Results are shown for one 663-Lyn
WT clone and one 663-Lyn
Y397F clone. Experiments were performed with another clone in each category
and similar results were obtained. *indicates statistical significance by student t test: P,.05 compared with the control neo-cells.
doi:10.1371/journal.pone.0005721.g005
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Y397F cells in the
presence of Epo was reduced compared with control cells
indicating that the dominant negative Lyn mutant was able to
counteract the ability of Lyn to favor Epo-induced proliferation
(Figure 5D). An opposite effect of Lyn was seen when cells were
grown with SCF. Indeed, the growth rate of 663-Lyn
WT cells in
the presence of SCF was reduced compared to 663-neo cells
(Figure 5C). Thus, the intracellular presence of Lyn was not
compatible with the expansion of proerythroblastic cells in the
presence of SCF. This result is consistent with the ability of Lyn to
down-regulate Kit expression.
Discussion
During erythropoiesis, SCF and Epo tightly control the pool size
of erythroid progenitor cells that will survive, divide or
differentiate. From CFU-E to erythroblasts, the subtle balance
between Epo and SCF responses results from a gradual decline of
Kit expression associated to an increase in EpoR expression.
However, the signaling mechanisms underlying the down-
regulation of Kit and the up-regulation of EpoR are poorly
understood, mainly because of the poor accessibility, the rarity and
the transience of the CFU-E. The spi-1 transgenic proerythroblasts
no longer undergo differentiation and are arrested at the CFU-E/
proerythroblast transition, but these cells retain their dependency
to Epo or SCF for survival and proliferation. This experimental
system, in which expansion is uncoupled from maturation, was
used to examine the mechanisms controlling the proliferative
responses of proerythroblasts to Epo or SCF. We show that Epo
down-regulates Kit expression and that Lyn kinase behaves as a
mediator of SCF signaling through controlling Kit expression.
The proerythroblastic cell lines derived from the spleen of
diseased spi-1 transgenic mice are morphologically [9] and
cytologically (our unpublished data) similar, and resemble CFU-
E/proerythroblastic cells. They have intrinsic proliferative capac-
ities and express Kit and EpoR at different levels. This
heterogeneity may reflect subtle differences in the level at which
the maturation arrest provoked by the overexpression of the spi-1
transgene occurred and/or to genetic or epigenetic variability in
the cell lines.
We took advantage of this heterogeneity to investigate the
molecular processes involved in the control of Kit and EpoR
expression in response to their cognate ligands. Each cell line (six
were studied and three are shown) had a proliferation rate in the
presence of SCF that was correlated with the level of Kit
expression. However, we observed that Kit levels were modulated
by the cytokine used to expand the cells (Epo versus SCF) and that
this modulation was rapidly reversible by a change in cytokine.
Modifications in Kit levels were detected both in whole cell
extracts and at the cell surface indicating that they in fine may lead
to a modified response to SCF. The variations in surface
expression of Kit analyzed by flow cytometry were significantly
lower than that of total amount of cellular Kit analyzed by SDS-
PAGE. These differences might be a consequence of the
occurrence of Kit receptor internalization following SCF-induced
activation [23,24]. Because of the unavailability of EpoR
antibodies for flow cytometric analysis, determination of the cell
surface expression of EpoR was not performed. However, no
obvious variation in EpoR expression could be detected in whole
cell extracts whether cells were stimulated with Epo or SCF. The
high Kit level in SCF-cultured cells was reminiscent of a
mechanism involving SCF as a modulator of its own receptor
expression as described for IL-3, CSF-1 and GM-CSF [25]. In
contrast, we observed that Kit expression was down-regulated by
Epo and that this down-regulation was inhibited by AG490, an
inhibitor of EpoR signaling.
During hematopoiesis, Kit is expressed in immature and lineage
progenitors and is down-regulated upon terminal erythroid
differentiation. Accordingly, SCF enhances proliferation and
retards differentiation of the erythroblasts and forced expression
of Kit in erythroid precursors impairs their maturation [26,27].
Different mechanisms leading to attenuation of Kit signaling have
been reported. A mechanism involves SCF binding to Kit that
induces a rapid internalization of the ligand-receptor complex and
its degradation through an ubiquitination process [28,29].
Another process refers to the down-regulation of Kit activation
by negative effectors such as the SH2-containing protein tyrosine
phosphatase SHP1 [30]. Such mechanisms can be ruled in our
system since Kit down-regulation was seen in the absence of SCF,
when cells were grown with Epo. Others mechanisms involve a
regulatory control at the Kit transcriptional level. In erythropoiesis,
transcription factors such as Tal-1 [31] and GATA-1 [27,32] are
repressors of Kit transcriptional expression. Our RT-PCR
experiments revealed evident differences in Kit transcripts levels
in cells cultured with Epo compared to cells cultured with SCF, a
higher expression of Kit transcripts being detected in SCF-cultured
cells. Though changes in mRNA stability are an alternate
mechanism to explain a variation in mRNA amount, it is
attempting to speculate that a transcriptional mechanism is most
probably involved in the regulation of Kit expression in
proerythroblastic cells. More investigations are required to
characterize such a mechanism. Our findings of the down-
regulation of Kit expression by Epo in the context of a late
erythroid progenitor at the transition CFU-E/proerythroblast
highlight that Epo is capable to switch off the expression of Kit in
maturing erythroblasts. This process may also limit the cooper-
ation between the two cytokines for proerythroblast proliferation
and survival.
Several laboratories have described synergistic features between
Kit and EpoR co-signaling to maintain the growth and survival of
erythroid progenitors in vitro [33–37]. One mechanism involves
EpoR as a direct downstream effector of Kit signaling through
transphosphorylation induced by SCF. More indirectly, Kit
signaling contributes to the sustained expression of Stat5 protein
which can then be activated by Epo [38]. Target gene products of
the EpoR-activated Stat5 axis can also contribute to enhance Kit
signaling [39]. Finally, in the human hematopoietic stem cell-like
cell line HML/SE, stimulation of Kit by SCF activates transcription
of the EpoR gene making the cells responsive to Epo [40]. Similarly,
we observed a cooperative effect between Epo and SCF for the
survival and proliferation of spi-1 transgenic proerythroblasts. It
should be noted that cooperation was seen only at a limiting Epo
concentration when Kit expression was up-regulated. In contrast,
when Epo was used at a suboptimal concentration (1 U/mL) in
combination with SCF, Epo was the only player in controlling cell
proliferation. It is reasonable to propose that the down-regulation of
Kit expression leads to the loss of SCF responsiveness. In this
regard, SCFandEpocooperation wouldbe restrictedtoearly stages
of erythropoiesis when Kit level is high. This agrees with data
localizing the physical interaction of Kit and EpoR before or at the
CFU-E stage [34] and with results indicating that elevated levels of
Epo abolish the requirement for SCF-mediated signals in in vivo
erythropoiesis [41].
Our findings add to our knowledge of Lyn action in
erythropoiesis. Analyses of Lyn-deficient mice revealed that
CFU-E exhibited a reduced proliferative capacity associated with
attenuated responses to Epo and SCF and that erythroblasts
presented defects in survival and maturation [42–44]. It was thus
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progenitors and the development of mature erythroblasts. Lyn has
been described as a downstream effector of Epo in promoting
erythroid differentiation [22,45]. Then, Lyn participates in Stat5
activation and phosphorylation of EpoR [46]. Our findings show
that Lyn sustains the Epo-dependent proliferation agreeing with a
role of Lyn in the proliferation of late erythroid precursor cells.
Furthermore, ectopic Lyn overexpression in SCF-cultured cells
resulted in a reduction in Kit expression making cells poorly
responsive to SCF. This observation underlines a dual role for Lyn
as a positive effector in Epo signaling and a negative effector in Kit
signaling and presents Lyn as a major mediator of the balance
between Epo and SCF responsiveness during proliferation of
proerythroblastic cells.
Stat5 phosphorylation is induced by Epo in erythroid cells
[19,47] and this activation depends on kinases associated with
EpoR: the Jak2 kinase [48] and tyrosine kinases of the Src family
such as Lyn in murine [22,46] and Src in human erythroblasts
[49,50]. Although the activation of Stat5 downstream of SCF/Kit
has been reported in the myeloid MO7e cells [51], it remains
infrequent. Indeed, Stat5 is not activated by SCF in the erythroid
cell lines HCD57 [35] and G1E-ER2 [38] as well as in primary
erythroid progenitors [52,53,54]. Similarly, we found that Stat5
was not activated by SCF in spi-1 transgenic proerythroblasts. In
contrast, Stat5 was activated by Epo. Because phosphorylated
Stat5 levels in cells cultured under Epo paralleled the expression
level of Lyn, a prediction could be that Stat5 was an effector
downstream of Lyn in Epo-dependent proliferation of cells.
Though Stat5 has been characterized as a direct substrat for
Lyn during Epo-induced differentiation of the J2E cell line [22], it
is not determined whether Lyn induces similar signaling during
cell proliferation in response to Epo. Alternatively, Lyn was an
Epo-responsive gene and could be a Stat5 transcriptional target
gene. Induction of Lyn protein expression by Epo was associated
to induction of RNA expression. Further investigation is required
to know whether Stat5 controls the transcription of Lyn through
direct binding to its transcriptional promoter.
In conclusion, our findings on the down-regulation of Kit
expression by the EpoR/Lyn pathway in the context of a late
erythroid progenitor cell (CFU-E/proerythroblast transition)
provide some insights into the mechanisms leading to Kit
extinction in maturing erythroblasts. We postulate that the control
of Kit expression during erythroid development results from
interference between Epo and SCF signaling where activation of
the EpoR/Lyn pathway would lead the proerythroblast to the
strict Epo dependency through mediating extinction of Kit
expression. In this light, it will be interesting to determine if such
a down-regulation of the activity of a cytokine active on early
multipotent progenitors by a cytokine active later on the
maturation of a lineage specific progenitor illustrates a general
process in the hematopoietic development.
Acknowledgments
The authors thank Z. Maciorowski (Cytometry department at Institut
Curie) for helpful assistance with flow cytometry and Janssen-Cilag (Issy-
les-Moulineaux, France) for the gift of recombinant human Epo. We are
grateful to C. Guillouf, P. Rimmele ´, M. Saison for many helpful discussions
and F. Wendling for comments on the manuscript.
Author Contributions
Conceived and designed the experiments: FMG. Performed the experi-
ments: OK DB IG ND. Analyzed the data: OK DB IG ND. Contributed
reagents/materials/analysis tools: OK FMG. Wrote the paper: FMG.
References
1. Munugalavadla V, Kapur R (2005) Role of c-Kit and erythropoietin receptor in
erythropoiesis. Crit Rev Oncol Hematol 54: 63–75.
2. Nocka K, Majumder S, Chabot B, Ray P, Cervone M, et al. (1989) Expression
of c-kit gene products in known cellular targets of W mutations in normal and W
mutant mice–evidence for an impaired c-kit kinase in mutant mice. Genes Dev
3: 816–826.
3. Geissler EN, Ryan MA, Housman DE (1988) The dominant-white spotting (W)
locus of the mouse encodes the c-kit proto-oncogene. Cell 55: 185–192.
4. Wu H, Liu X, Jaenisch R, Lodish HF (1995) Generation of committed erythroid
BFU-E and CFU-E progenitors does not require erythropoietin or the
erythropoietin receptor. Cell 83: 59–67.
5. Katayama N, Shih JP, Nishikawa S, Kina T, Clark SC, et al. (1993) Stage-
specific expression of c-kit protein by murine hematopoietic progenitors. Blood
82: 2353–2360.
6. Uoshima N, Ozawa M, Kimura S, Tanaka K, Wada K, et al. (1995) Changes in
c-Kit expression and effects of SCF during differentiation of human erythroid
progenitor cells. Br J Haematol 91: 30–36.
7. Fraser JK, Lin FK, Berridge MV (1988) Expression of high affinity receptors for
erythropoietin on human bone marrow cells and on the human erythroleukemic
cell line, HEL. Exp Hematol 16: 836–842.
8. Wognum AW, Lansdorp PM, Humphries RK, Krystal G (1990) Detection and
isolation of the erythropoietin receptor using biotinylated erythropoietin. Blood
76: 697–705.
9. Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, et al. (1996)
Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol
16: 2453–2463.
10. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, et al. (2005)
Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic
stem cells and their differentiation. Blood 106: 1590–1600.
11. Dakic A, Metcalf D, Di Rago L, Mifsud S, Wu L, et al. (2005) PU.1 regulates the
commitment of adult hematopoietic progenitors and restricts granulopoiesis.
J Exp Med 201: 1487–1502.
12. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, et al. (1996)
Targeted disruption of the PU.1 gene results in multiple hematopoietic
abnormalities. Embo J 15: 5647–5658.
13. Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, et al. (1997) PU.1
functions in a cell-autonomous manner to control the differentiation of
multipotential lymphoid-myeloid progenitors. Immunity 6: 437–447.
14. Rimmele P, Kosmider O, Mayeux P, Moreau-Gachelin F, Guillouf C (2007)
Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in
cooperation with Epo signaling and by blocking erythroid differentiation. Blood
109: 3007–3014.
15. Guillemin K, Krasnow MA (1997) The hypoxic response: huffing and HIFing.
Cell 89: 9–12.
16. Barnache S, Mayeux P, Payrastre B, Moreau-Gachelin F (2001) Alterations of
the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling
pathways in the erythropoietin-independent Spi- 1/PU.1 transgenic proeryth-
roblasts. Blood 98: 2372–2381.
17. Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, et al. (2003) Signal
transduction by several KIT juxtamembrane domain mutations. Oncogene 22:
4710–4722.
18. Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, et al. (2005) Kit-
activating mutations cooperate with Spi-1/PU.1 overexpression to promote
tumorigenic progression during erythroleukemia in mice. Cancer Cell 8:
467–478.
19. Gouilleux F, Pallard C, Dusanter-Fourt I, Wakao H, Haldosen LA, et al. (1995)
Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony
stimulating factor induce MGF-Stat5 DNA binding activity. Embo J 14:
2005–2013.
20. Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A (1995) Interleukin 2
and erythropoietin activate STAT5/MGF via distinct pathways. Embo J 14:
2527–2535.
21. Tan BL, Hong L, Munugalavadla V, Kapur R (2003) Functional and
biochemical consequences of abrogating the activation of multiple diverse early
signaling pathways in Kit. Role for Src kinase pathway in Kit-induced
cooperation with erythropoietin receptor. J Biol Chem 278: 11686–11695.
22. Tilbrook PA, Ingley E, Williams JH, Hibbs ML, Klinken SP (1997) Lyn tyrosine
kinase is essential for erythropoietin-induced differentiation of J2E erythroid
cells. Embo J 16: 1610–1619.
23. Broudy VC, Lin NL, Liles WC, Corey SJ, O’Laughlin B, et al. (1999) Signaling
via Src family kinases is required for normal internalization of the receptor c-Kit.
Blood 94: 1979–1986.
24. Jahn T, Seipel P, Coutinho S, Urschel S, Schwarz K, et al. (2002) Analysing c-kit
internalization using a functional c-kit-EGFP chimera containing the fluoro-
chrome within the extracellular domain. Oncogene 21: 4508–4520.
25. Panterne B, Hatzfeld A, Sansilvestri P, Cardoso A, Monier MN, et al. (1996) IL-
3, GM-CSF and CSF-1 modulate c-fms mRNA more rapidly in human early
Down-Regulation of Kit by Epo
PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5721monocytic progenitors than in mature or transformed monocytic cells. J Cell Sci
109 (Pt 7): 1795–1801.
26. Muta K, Krantz SB, Bondurant MC, Dai CH (1995) Stem cell factor retards
differentiation of normal human erythroid progenitor cells while stimulating
proliferation. Blood 86: 572–580.
27. Munugalavadla V, Dore LC, Tan BL, Hong L, Vishnu M, et al. (2005)
Repression of c-kit and its downstream substrates by GATA-1 inhibits cell
proliferation during erythroid maturation. Mol Cell Biol 25: 6747–6759.
28. Yee NS, Hsiau CW, Serve H, Vosseller K, Besmer P (1994) Mechanism of
down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phospha-
tidylinositol 39-kinase, and protein kinase C. J Biol Chem 269: 31991–31998.
29. Miyazawa K, Toyama K, Gotoh A, Hendrie PC, Mantel C, et al. (1994) Ligand-
dependent polyubiquitination of c-kit gene product: a possible mechanism of
receptor down modulation in M07e cells. Blood 83: 137–145.
30. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, et al. (1998) SHP-1 binds
and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in
the c-Kit juxtamembrane domain. Mol Cell Biol 18: 2089–2099.
31. Vitelli L, Condorelli G, Lulli V, Hoang T, Luchetti L, et al. (2000) A pentamer
transcriptional complex including tal-1 and retinoblastoma protein down-
modulates c-kit expression in normal erythroblasts. Mol Cell Biol 20:
5330–5342.
32. Jing H, Vakoc CR, Ying L, Mandat S, Wang H, et al. (2008) Exchange of
GATA factors mediates transitions in looped chromatin organization at a
developmentally regulated gene locus. Mol Cell 29: 232–242.
33. Wu H, Klingmuller U, Besmer P, Lodish HF (1995) Interaction of the
erythropoietin and stem-cell-factor receptors. Nature 377: 242–246.
34. Wu H, Klingmuller U, Acurio A, Hsiao JG, Lodish HF (1997) Functional
interaction of erythropoietin and stem cell factor receptors is essential for
erythroid colony formation. Proc Natl Acad Sci USA 94: 1806–1810.
35. Jacobs-Helber SM, Penta K, Sun Z, Lawson A, Sawyer ST (1997) Distinct
signaling from stem cell factor and erythropoietin in HCD57 cells. J Biol Chem
272: 6850–6853.
36. Panzenbock B, Bartunek P, Mapara MY, Zenke M (1998) Growth and
differentiation of human stem cell factor/erythropoietin- dependent erythroid
progenitor cells in vitro. Blood 92: 3658–3668.
37. von Lindern M, Zauner W, Mellitzer G, Steinlein P, Fritsch G, et al. (1999) The
glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to
enhance and sustain proliferation of erythroid progenitors in vitro. Blood 94:
550–559.
38. Kapur R, Zhang L (2001) A novel mechanism of cooperation between c-Kit and
erythropoietin receptor. Stem cell factor induces the expression of Stat5 and
erythropoietin receptor, resulting in efficient proliferation and survival by
erythropoietin. J Biol Chem 276: 1099–1106.
39. Li K, Miller C, Hegde S, Wojchowski D (2003) Roles for an Epo receptor Tyr-
343 Stat5 pathway in proliferative co-signaling with kit. J Biol Chem 278:
40702–40709.
40. Sato T, Watanabe S, Ishii E, Tsuji K, Nakahata T (1998) Induction of the
erythropoietin receptor gene and acquisition of responsiveness to erythropoietin
by stem cell factor in HML/SE, a human leukemic cell line. J Biol Chem 273:
16921–16926.
41. Waskow C, Terszowski G, Costa C, Gassmann M, Rodewald HR (2004) Rescue
of lethal c-KitW/W mice by erythropoietin. Blood 104: 1688–1695.
42. Harder KW, Parsons LM, Armes J, Evans N, Kountouri N, et al. (2001) Gain-
and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in
the myeloid lineage. Immunity 15: 603–615.
43. Harder KW, Quilici C, Naik E, Inglese M, Kountouri N, et al. (2004) Perturbed
myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the
inhibitory phosphatases SHP-1 and SHIP-1. Blood 104: 3901–3910.
44. Karur VG, Lowell CA, Besmer P, Agosti V, Wojchowski DM (2006) Lyn kinase
promotes erythroblast expansion and late-stage development. Blood 108:
1524–1532.
45. Tilbrook PA, Palmer GA, Bittorf T, McCarthy DJ, Wright MJ, et al. (2001)
Maturation of erythroid cells and erythroleukemia development are affected by
the kinase activity of Lyn. Cancer Res 61: 2453–2458.
46. Chin H, Arai A, Wakao H, Kamiyama R, Miyasaka N, et al. (1998) Lyn
physically associates with the erythropoietin receptor and may play a role in
activation of the Stat5 pathway. Blood 91: 3734–3745.
47. Penta K, Sawyer ST (1995) Erythropoietin induces the tyrosine phosphorylation,
nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid
cells. J Biol Chem 270: 31282–31287.
48. Witthuhn BA, Quelle FW, Silvennoinen O, Yi T, Tang B, et al. (1993) JAK2
associates with the erythropoietin receptor and is tyrosine phosphorylated and
activated following stimulation with erythropoietin. Cell 74: 227–236.
49. Kubota Y, Tanaka T, Kitanaka A, Ohnishi H, Okutani Y, et al. (2001) Src
transduces erythropoietin-induced differentiation signals through phosphatidy-
linositol 3-kinase. Embo J 20: 5666–5677.
50. Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, et al. (2001) Src
directly tyrosine-phosphorylates STAT5 on its activation site and is involved in
erythropoietin-induced signaling pathway. Oncogene 20: 6643–6650.
51. Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L (1999) STAT protein
recruitment and activation in c-Kit deletion mutants. J Biol Chem 274:
16965–16972.
52. Pircher TJ, Geiger JN, Zhang D, Miller CP, Gaines P, et al. (2001) Integrative
signaling by minimal erythropoietin receptor forms and c-Kit. J Biol Chem 276:
8995–9002.
53. Arcasoy MO, Jiang X (2005) Co-operative signalling mechanisms required for
erythroid precursor expansion in response to erythropoietin and stem cell factor.
Br J Haematol 130: 121–129.
54. Menon MP, Karur V, Bogacheva O, Bogachev O, Cuetara B, et al. (2006)
Signals for stress erythropoiesis are integrated via an erythropoietin receptor-
phosphotyrosine-343-Stat5 axis. J Clin Invest 116: 683–694.
Down-Regulation of Kit by Epo
PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5721